

Supporting Information

Cation-Halide Transport through Peptide Pores containing Aminopicolinic Acid

Debajyoti Basak[†], Sucheta Sridhar[‡], Amal K. Bera^{*‡} and Nandita Madhavan^{*†}

[†] Department of Chemistry and [‡]Department of Biotechnology Indian Institute of Technology Madras, Chennai – 600036, Tamil Nadu, India.

amal@iitm.ac.in, nanditam@iitm.ac.in

Table of Contents

General Methods	S2
Synthesis of Aminopicoline derivative 6	S3
Synthesis of octapeptide 1	S5
Synthesis of octapeptide 2	S11
Vesicle based fluorescence experiments	S15
a) HPTS assay in HEPES-NaCl buffer	S15
b) Lucigenin assay with sodium halides	S19
c) Lucigenin assay with metal chlorides	S21
i) Peptide added after addition of salt	S21
ii) Peptide premixed with vesicle	S27
Dynamic light scattering studies	S33
TEM studies	S34
Planar lipid bilayer experiment	S34
Absorbance Measurements of Peptides with CoCl ₂ and NiCl ₂	S35
References and notes	S36
Spectra of compounds	S37

General Methods

All reagents for synthesis were purchased from commercial suppliers and used without further purification unless stated otherwise. All air-sensitive reactions were performed using oven-dried glassware in an inert atmosphere of nitrogen. Syringe or cannula was used to transfer air-sensitive solvents and solutions. Dichloromethane and *N,N*-diisopropylethylamine (DIEA) were distilled over calcium hydride, methanol was distilled over magnesium oxide and *N,N*-dimethylformamide (DMF) was dried over 4 Å molecular sieves. All dry solvents were stored over 4 Å molecular sieves prior to use. All peptides were synthesized in solution using *O*-(6-chlorobenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (HCTU) as a coupling reagent and *N,N*-diisopropylethylamine (DIEA) as base. Egg yolk phosphatidyl choline (EYPC) and 8-hydroxypyrene-1,3,6 trisulfonic acid, trisodium salt (HPTS) and *N,N'*-dimethyl-9,9'-biacridinium dinitrate (Lucigenin) were purchased from Sigma-Aldrich and used without further purification.


Analytical thin layer chromatography (TLC) was performed on MERCK precoated silica gel 60 F₂₅₄TLC plates. Eluting solvents are reported as volume percents. Compounds were visualized using UV light and ninhydrin. Flash column chromatography was performed using silica gel from Acme chemicals and active aluminium oxide from Fischer Scientific. All NMR spectra were recorded on Bruker 500 spectrometers using CDCl₃, or DMSO-d₆ as solvent. The NMR spectra were referenced using residual solvent peaks as the standard. Chemical shifts are denoted in parts per million (δ), coupling constants (*J*) are reported in Hertz (Hz), and spin multiplicities are reported as singlet (s), doublet (d), triplet (t), quartet (q), quintet (quint), apparent quintet (app. quint.), multiplet (m). High resolution mass spectra (HRMS) were recorded on the MICRO-Q-TOF mass spectrometer using the ESI technique. FT-IR spectra were recorded on a JASCO FT/IR-4100 spectrometer. All IR spectra were recorded in the form of KBr pellet. IR spectra peaks are reported in wave numbers (cm⁻¹) as strong (s) and broad (br).

Vesicles were prepared from EYPC lipids using Mini extruder from Avanti Polar Lipids. Conductivity water was used for the preparation of buffers and vesicles. Vesicles were prepared at room temperature in a suitable buffer for the HPTS assay and the buffer pH was adjusted to 7.2 with concentrated NaOH solution. The pH was checked with ^{L1}613 pH meter from Vanira Instruments. Vesicles were prepared in an aqueous solution of 225 mM NaNO₃ for the lucigenin assays. Extrusion of vesicles was carried out through 0.1 μ m polycarbonate membranes

(Whatman) using the mini extruder from Avanti Polar Lipid. Size exclusion chromatography was carried out using Sephadex (G-50) resin. Fluorescence spectra were recorded on a JASCO FP-6300 fluorescence spectrofluorometer using a 3 mL quartz cuvette. A small magnetic stir plate was placed beside the cuvette holder to ensure that the cuvette solutions could be stirred. All graphs were plotted and fitted using Origin Pro8 software. Dynamic light scattering data was recorded on a Malvern Zetasizer ZS instrument using 3 mL quartz cells. For absorbance measurement, A JascoV-650 spectrophotometer equipped with a 1 cm path length quartz cell was used. PMT voltage was kept at 700 V and scans speed at 1,000 nm min⁻¹ with the band pass of 2 nm.

Synthesis of Aminopicoline derivative 6:¹

Scheme S1



***N*-acetyl 6-aminopicoline 16:** To a solution of 6-aminopicoline **15** (15.0 g, 139.0 mmol, 1.0 equiv) in chloroform (75 mL) was slowly added acetic anhydride (19.7 mL, 208.0 mmol, 1.5 equiv) and the reaction mixture was heated to 80 °C for 1 h. The reaction mixture was diluted with chloroform (15 mL) and washed sequentially with water (2 × 25 mL), saturated aqueous NaHCO₃ (2 × 25 mL) and water (1 × 25 mL). The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated in vacuo. The crude residue was recrystallized using hexane to afford 18.5 g (89%) of *N*-acetyl 6-aminopicoline **16** as a white solid. TLC R_f = 0.20 (10% ethyl acetate/ hexane).

¹H NMR (500 MHz, CDCl₃, 25 °C) δ 8.66 (s, 1H; NH_{Ar}), 7.98 (d, *J* = 8.0 Hz, 1H; H_{Ar}), 7.57 (t, *J* = 7.5 Hz, 1H; H_{Ar}), 6.86 (d, *J* = 7.5, 1H; H_{Ar}), 2.42 (s, 3H; CH_{3(Ar)}), 2.14 (s, 3H; CH₃); ¹³C NMR (125 MHz, CDCl₃, 25 °C) δ 168.9, 156.3, 150.7, 139.1, 119.3, 111.2, 24.7, 23.8; IR (KBr pellet): ν 3243 (b), 3061 (s), 1666 (b), 1545 (b), 1453(s), 1368 (s), 1305 (b), 1156 (s) cm⁻¹; HRMS: (ESI⁺) calcd for C₈H₁₁N₂O (MH)⁺ 151.0871, found 151.0877.

***N*-acetyl-6-aminopicolinic acid 17:** KMnO₄ (28.5 g, 183.0 mmol, 2.5 equiv) was added in portions to a suspension of *N*-acetyl-6-aminopicoline **16** (11.0 g, 73.2 mmol, 1.0 equiv) in water. The reaction mixture was heated to 80 °C for 5 h, following which it was filtered through celite. The precipitate was washed with hot water (2 × 25 mL). The filtrate was concentrated to one third of its original volume and cooled in an ice bath. *N*-acetyl-6-aminopicolinic acid **17** (8.5 g, 65%) was obtained as a white precipitate after slow addition of hydrochloric acid (12 M). TLC R_f = 0.07 (10% ethyl acetate/ methanol). The white solid was used for the next step without further purification.


¹H NMR (500 MHz, DMSO-d₆) δ 10.91 (s, 1H; NH_{Ar}), 8.24 (d, *J* = 8.0 Hz, 1H; H_{Ar}), 7.95 (t, *J* = 8.0 Hz, 1H; H_{Ar}), 7.73 (dd, *J* = 7.5 Hz, 1H; H_{Ar}), 5.30 (s, 1H; OH), 2.11 (s, 3H; CH₃); **¹³C NMR** (125 MHz, CDCl₃, 25 °C) overlapping peaks δ 170.1, 165.7, 151.9, 139.8, 120.2, 117.0, 23.9; **IR** (KBr pellet): ν 3340 (b), 2923 (b), 1947 (b), 1728 (s), 1632(s), 1575 (s), 1487 (s), 1430 (s), 1290 (s), 1236 (s), 772(s) cm⁻¹; **HRMS:** (ESI⁺) calcd for C₈H₈N₂O₃Na (MNa)⁺ 203.0433, found 203.0430.

Methyl ester 6: To a solution of *N*-acetyl-6-aminopicolinic acid **17** (0.3 g, 1.8 mmol, 1 equiv) in methanol (25.0 mL, 0.61 mol, 320.0 equiv) was slowly added hydrochloric acid (12 M, 7.5 mL). The reaction mixture was allowed to reflux for 72 h. The residue was neutralized with saturated aqueous NaHCO₃ (30 mL), diluted with water (25 mL) and extracted with ethyl acetate (4 × 25 mL). The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated in vacuo. Purification by column chromatography (50% ethyl acetate/ hexane) afforded 0.2 g (77%) of methyl ester **6** as a pale yellow solid. TLC R_f = 0.30 (50% ethyl acetate/ hexane).

¹H NMR (500 MHz, CDCl₃, 25 °C) δ 7.57 (t, *J* = 8.0 Hz, 1H; H_{Ar}), 7.44 (d, *J* = 7.5 Hz, 1H; H_{Ar}), 6.84 (d, *J* = 8.5 Hz, 1H; H_{Ar}), 3.96 (s, 3H; CH₃) **¹³C NMR** (125 MHz, CDCl₃, 25 °C) δ 165.1, 158.0, 144.0, 139.1, 115.6, 114.2, 53.1; **IR** (KBr pellet): ν 3471 (s), 3362 (s), 1716(s), 1608 (s), 1468 (s), 1351 (s), 1267 (s) cm⁻¹. **HRMS:** (ESI⁺) calcd for C₇H₉N₂O₂ (MH)⁺ 153.0664, found 153.0666.

Synthesis of octapeptide **1**²

Scheme S2



BOC-L-Ala- D-Ala-OMe 20: To a solution of Boc-L-Alanine **19** (0.6 g, 3.1 mmol, 1.0 equiv) and D-Ala-OMe **18** (0.4 g, 3.1 mmol, 1.0 equiv) in CH₂Cl₂ (7.0 mL) was added HCTU (1.5 g, 3.6 mmol, 1.2 equiv). DIEA (2.1 mL, 9.2 mmol, 3.0 equiv) was slowly added and the reaction mixture was allowed to stir at RT for 6 h. The solvent was evaporated in vacuo and the residue

was diluted with ethyl acetate (15 mL). The solution was sequentially washed with water (2×15 mL), 5% HCl (2×15 mL), saturated aqueous NaHCO₃ (2×15 mL) and water (2×15 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. Purification by column chromatography (30 % ethyl acetate/ hexane) afforded 0.7 g (84%) of dipeptide **20** as a white solid. TLC R_f= 0.15 (10% ethyl acetate/ hexane).

¹H NMR (500 MHz, DMSO-*d*₆, 25 °C) δ 8.15 (d, *J* = 7.5, 1H; NH_{Ala}), 6.82 (s, 1H; NHBoc), 4.26 (app quint, 1H; CH_{Ala}), 4.0 (app quint, 1 H; CH_{Ala}), 3.62 (s, 3H; OCH₃), 1.37 (s, 9H; (CH₃)₃C), 1.26 (d, *J* = 7.5 Hz, 3H; CH_{3(Ala)}), 1.16 (d, *J* = 7 Hz, 3H; CH_{3(Ala)}); **¹³C NMR** (125 MHz, DMSO-*d*₆, 25 °C) δ 173.0, 172.6, 154.9, 78.0, 51.9, 49.5, 47.5, 28.2, 18.4, 17.2; **IR** (KBr pellet): ν 3368 (s), 3290 (b), 2983 (s), 1751(s), 1699 (s), 1644 (b), 1542 (s), 1507 (s), 1454 (s), 1366 (s), 1299 (s), 1251 (s), 1162 (b) cm⁻¹; **HRMS (ESI⁺)**: calcd for C₁₂H₂₂N₂O₅Na (MNa)⁺ 297.1426; found 297.1439.

BOC-L-Ala- D-Ala-OH 21: To a solution of dipeptide **20** (0.6 g, 2.2 mmol, 1.0 equiv) in THF (6 mL) were added LiOH (0.2 g, 5.5 mmol, 2.5 equiv) and water (4 mL). The reaction mixture was allowed to stir at RT for 4 h, following which it was diluted with water (10 mL) and washed with ethyl acetate (10 mL). The aqueous layer was acidified with dil HCl to a pH of 1 and was extracted with ethyl acetate (4×15 mL). The organic layer was dried over anhydrous sodium sulphate and concentrating in vacuo to afford 0.5 g (93%) of dipeptide **21** as a white solid. TLC R_f= 0.25 (100% ethyl acetate).

¹H NMR (500 MHz, DMSO-*d*₆) δ 12.55 (s, 1H; OH), 7.98 (d, *J* = 7.5 Hz, 1H; NH_{Ala}), 6.82 (s, 1H; NHBoc), 4.19 (app. quint, 1 H; CH_(Ala)), 4.0 (app. quint, 1 H; CH_(Ala)), 1.37 (s, 9H; (CH₃)₃C), 1.25 (d, *J* = 7 Hz, 3H; CH_{3(Ala)}) 1.16 (d, *J* = 7.5 Hz, 3H; CH_{3(Ala)}); **¹³C NMR** (125 MHz, DMSO-*d*₆) δ 174.0, 172.4, 154.9, 78.1, 49.5, 47.4, 28.2, 18.5, 17.5; **IR** (KBr pellet): ν 3327 (b), 3270 (b), 2982 (s), 1720 (s), 1682 (s), 1638 (S), 1564 (s), 1378 (s), 1257 (s), 1170 (s) cm⁻¹; **HRMS:(ESI⁺)** calcd for C₁₁H₂₁N₂O₅ (MH)⁺ 261.1450; found 261.1443.

OMe-AP-L-Ala-Boc 7: To a solution of methyl 6-aminopicolinate **6** (0.4 g, 2.9 mmol, 1.0 equiv) and Boc-L-Alanine (0.6 g, 3.2 mmol, 1.1 equiv) in CH₂Cl₂ (7.0 mL) was added HCTU (1.3 g, 3.2 mmol, 1.1 equiv). DIEA (2.0 mL, 8.7 mmol, 3.0 equiv) was slowly added and the reaction mixture was allowed to stir at RT for 12 h. The solvent was evaporated in vacuo, following which the residue was diluted with ethyl acetate (15 mL). The solution was washed sequentially with water (2 × 15 mL), 5% HCl (2 × 15 mL), saturated aqueous NaHCO₃ (2 × 15 mL) and water (15 mL). The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated in vacuo. Purification by column chromatography (30% ethyl acetate/ hexane) afforded 0.7 g (75%) of dipeptide **7** as a white solid. TLC R_f = 0.30 (40% ethyl acetate/ hexane).

¹H NMR (500 MHz, DMSO-*d*₆, 25 °C) δ 10.81 (s, 1H; NH_{Ar}), 8.31 (d, *J* = 8.5 Hz, 1H; H_{Ar}), 7.98 (t, *J* = 8.5 Hz, 1H; H_{Ar}), 7.77 (d, *J* = 7.5 Hz, H_{Ar}), 7.14 (d, *J* = 7.5 Hz, 1H; NHBoc), 4.26 (app. quint, 1H; CH_{Ala}), 3.87 (s, 3H; OCH₃), 1.37 (s, 9H; (CH₃)₃C), 1.25 (d, *J* = 7.5 Hz, 3H; CH_{3(Ala)}); ¹³C NMR (125 MHz, DMSO-*d*₆, 25 °C) δ 173.5, 164.9, 155.2, 152.0, 145.8, 139.7, 120.4, 117.4, 78.1, 52.4, 50.3, 28.2, 17.8; IR (KBr pellet): ν 3298 (b), 2979 (s), 1713 (s), 1680 (s), 1539 (s), 1449 (s), 1307 (s), 1166 (s), 771 (s) cm⁻¹; HRMS (ESI⁺): calcd for C₁₅H₂₂N₃O₅ (MH)⁺ 324.1559, found 324.1553.

NH₂-L-Ala-AP-OMe 22: To a solution of dipeptide **7** (0.3 g, 0.9 mmol, 1.0 equiv) in DCM (7 mL) was added trifluoroacetic acid (0.6 mL, 8.3 mmol, 10.0 equiv) and the reaction mixture was allowed to stir for 3 h at RT. The solvent was evaporated in vacuo. The residue was dissolved in water and lyophilized to afford 0.3 g (95%) of dipeptide **22** as a pale yellow solid. TLC R_f = 0.10 (10% MeOH/ DCM).

¹H NMR (500 MHz, DMSO-*d*₆, 25 °C) δ 11.40 (s, 1H; NH_{Ar}), 8.32 (s, 3H; NH₂, H_{Ar}), 8.06 (t, *J* = 7.5 Hz, 1H; H_{Ar}), 7.84 (d, *J* = 7.5 Hz, 1H; H_{Ar}), 4.19 – 4.09 (m, 1H; CH_(Ala)), 3.88 (s, 3H; OCH₃), 1.45 (d, *J* = 6.5 Hz, 3H; CH_{3(Ala)}); ¹³C NMR (125 MHz, DMSO-*d*₆, 25 °C) δ 169.7, 164.7, 151.3, 145.9, 140.2, 121.1, 117.5, 52.5, 49.0, 17.1; IR (KBr pellet): ν 3237 (b), 3045 (b), 1673 (b), 1536 (s), 1447 (s), 1314 (s), 1198 (b), 1136 (s) cm⁻¹. HRMS: (ESI⁺) calcd for C₁₀H₁₄N₃O₃ (MH)⁺ 224.1035; found 224.1026.

OMe-AP-L-Ala- D-Ala--L-Ala-Boc 8: To a solution of dipeptide **21** (0.24 g, 0.90 mmol, 1.0 equiv) and dipeptide **22** (0.3 g, 0.9 mmol, 1.0 equiv) in dry DCM (7 mL) was added HCTU (0.42 g, 1.03 mmol, 1.2 equiv). DIEA (0.44 mL, 2.6 mmol, 3.0 equiv) was slowly added to the reaction mixture and the solution was allowed to stir for 12 h at RT. The solvent was evaporated in vacuo and the residue was diluted with ethyl acetate (15 mL). The solution was sequentially washed with water (2 × 15 mL), 5% HCl (2 × 15 mL), saturated aqueous NaHCO₃ (2 × 15 mL) and water (15 mL). The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated in vacuo. Purified by column chromatography (silica gel; 30% - 60% ethyl acetate in hexane, v/v) to afford 0.29 g (70%) of tetrapeptide **8** as a white solid. TLC R_f = 0.2 (50% ethyl acetate/hexane).

¹H NMR (500 MHz, DMSO-d₆) δ 10.90 (t, *J* = 14.5 Hz, 1H; NH_{Ar}), 8.29 (t, *J* = 9.5 Hz, 1H; H_{Ar}), 8.15-8.05 (m (rotamers observed), 1H; NH_{Ala}), 7.98 (t, *J* = 7.5 Hz, 1H; H_{Ar}), 7.93 (t, *J* = 6.0 Hz, 1H; NH_{Ala}), 7.78 (dd, *J* = 8.0 Hz, 1.5 Hz; H_{Ar}), 7.0-6.91 (m, 1H; NHBoc), 4.58 – 4.41 (m (rotamers observed), 1H; CH_(Ala)), 4.35 – 4.25 (m, 1H; CH_(Ala)), 3.95 (app. quint; CH_(Ala)), 3.87 (s, 3H; OCH₃), 1.38- 1.27 (12H; (CH₃)₃C and CH_{3(Ala)}), 1.22- 1.19 (m, 3H; CH_{3(Ala)}), 1.15 (d, *J* = 7 Hz, 3H; CH_{3(Ala)}); ¹³C NMR (125 MHz, DMSO-d₆) δ 172.6, 172.4, 171.9, 164.8, 155.1, 151.9, 145.8, 139.6, 120.4, 117.4, 78.1, 52.4, 49.8, 49.0, 48.0, 28.2, 18.5, 18.1, 17.9; IR (KBr pellet): ν 3347 (b), 1703 (b), 1529 (s), 1453 (s), 1377 (s), 1310 (s), 1166 (b). HRMS: (ESI⁺) calcd for C₂₁H₃₂N₅O₇ (MH)⁺ 466.2302; found 466.2294.

OMe-AP-L-Ala- D-Ala--L-Ala-NH₂ 9: To a solution of tetrapeptide **8** (0.18 g, 0.37 mmol, 1.0 equiv) in CH₂Cl₂ (7 mL) was slowly added trifluoroacetic acid (0.2 mL, 3.7 mmol, 10.0 equiv) over the period of 5 minutes using a syringe. The reaction mixture was allowed to stir for 4 h at RT. The solvent was evaporated in vacuo and the resultant salt was dissolved in water (2 mL) and lyophilized to afford 0.18 gm (99%) of product **9** as a pale yellow solid. TLC R_f = 0.10 (15% MeOH/ DCM).

¹H NMR (500 MHz, DMSO-d₆, 25 °C) δ 10.92 (s, 1H; NH_{Ar} (small peak at 10.86 due to rotamer)), 8.60 (d, *J* = 5.5 Hz, 1H; NH_{Ala}), 8.4- 8.31 (m, 1H; NH_{Ala}), 8.28 (d, *J* = 8.5 Hz, 1H;

H_{Ar}), 8.10 (s, 3H; NH_3^+), 7.98 (t, $J = 8.0$ Hz, 1H; H_{Ar}), 7.78 (d, $J = 7.5$ Hz, 1H; H_{Ar}), 4.6- 4.36 (3H; 3 $CH_{(Ala)}$), 3.87 (s, 3H; OCH_3), 1.35- 1.28 (6H; 2 $CH_{3(Ala)}$), 1.24 (d, $J = 7.0$ Hz, 3H; $CH_{3(Ala)}$); ^{13}C NMR (125 MHz, DMSO- d_6 , 25 °C) δ 172.7, 171.6, 169.1, 164.9, 152.0, 145.9, 139.7, 120.6, 117.4, 69.8, 52.5, 49.0, 48.2, 18.9 18.3, 18.0, 17.9, 17.8, 17.32, 17.26; IR (KBr pellet): ν 3315(b), 2980(s), 2933(s), 1657(b), 1532(b), 1456(s), 1250(s), 1168(s). HRMS: (ESI $^+$) calcd for $C_{16}H_{24}N_5O_5$ (M+H) $^+$ 366.1777; found 366.1795.

OH-AP-L-Ala- D-Ala--L-Ala-Boc 10: A solution of tetrapeptide **8** (0.05 g, 0.11 mmol, 1.0 equiv) in methanol/ water (2:1) (6 mL) was treated with LiOH (0.02 g, 0.57 mmol, 5.0 equiv) at RT. The solution was allowed to stir for 6 h, following which methanol was evaporated in vacuo. The aqueous layer was diluted with water (5 mL), washed with ethyl acetate (10 mL), acidified with 5% aq. HCl and extracted with ethyl acetate (3 \times 10 mL). The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated in vacuo to afford 0.04 g (80%) of tetrapeptide **10** as a white solid. The white solid was used for the next step without further purification. TLC $R_f = 0.10$ (100% ethyl acetate)


IR (KBr pellet): ν 3239(b), 3087 (b), 1676 (b), 1542(s), 1456(s), 1313(s), 1252 (s), 1203(s), 1136 (s); HRMS: (ESI $^+$) calcd for $C_{20}H_{30}N_5O_7$ (MH) $^+$ 452.2145; found 452.2123.

OMe-AP-L-Ala- D-Ala--L-Ala-AP-L-Ala- D-Ala--L-Ala-Boc 1: To a solution of Boc deprotected tetrapeptide **9** (0.10 g, 0.21 mmol, 1.0 equiv) and ester deprotected tetrapeptide **10** (0.10 g, 0.22 mmol, 1.00 equiv) in CH_2Cl_2 (10 mL) was added HCTU (0.12 gm, 0.23 mmol, 1.10 equiv). DIEA (0.12 mL, 0.64 mol, 3.0 equiv) was slowly added to the reaction mixture and the solution was allowed to stir for 20 h at room temperature. The solvent was evaporated in vacuo and the residue was diluted with ethyl acetate (15 mL). The solution was washed with water (4 \times 15 mL). The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated in vacuo. Purification by column chromatography (neutral alumina; 50% – 80% ethyl acetate in hexane, v/v) afforded 0.14 g (77%) of octapeptide **1** as a pale yellow solid. TLC $R_f = 0.20$ (75% ethyl acetate/ hexane); $[\alpha]_D^{33} +6.75$ (c 1.0, $CHCl_3$).

¹H NMR (500 MHz, DMSO-*d*₆, 25 °C) δ 10.82 (s, 1H; *NH*_{Ar}), 10.64 (s, 1H; *NH*_{Ar}), 8.70 (d, *J* = 7.0 Hz, 1H; *NH*), 8.50 (d, *J* = 8.0 Hz, 1H; *NH*), 8.41- 8.32 (2H; *NH*), 8.25- 8.15 (3H; *NH*, 2 *H*_{Ar}), 8.0- 7.94 (2H; *H*_{Ar}), 7.78-7.65 (2H; *H*_{Ar}), 7.17 (d, *J* = 6.5 Hz, 1H; *NHBoc*), 4.65 – 4.5 (3H; 3 *CH*_(Ala)), 4.32-4.20 (2H; 2 *CH*_(Ala)), 4.12 (app. q, 1H; *CH*_(Ala)), 3.61 (s, 3H; *OCH*₃), 1.37 (s, 9H; (*CH*₃)₃C), 1.35-1.28 (9H; 3 *CH*_{3(Ala)}), 1.26 - 1.22 (9H; 3 *CH*_{3(Ala)}); **¹³C NMR** (125 MHz, DMSO-*d*₆, 25 °C) multiple peaks δ, 173.4, 173.0, 172.6, 172.1, 172.0, 171.9, 162.8, 162.5, 155.4, 151.0, 150.9, 148.0, 147.9, 140.0, 117.4, 117.3, 116.6, 78.3, 52.1, 50.9, 50.4, 49.1, 48.5, 48.0, 31.7, 29.2, 28.4, 24.5, 23.3, 21.3, 19.8, 18.1; **IR** (KBr pellet): ν 3459 (br), 3282 (s), 2926(s), 1634 (s), 1528 (s), 1453 (s), 1166 (s) cm⁻¹; **HRMS**: (ESI⁺) Calculated for C₃₆H₅₀N₁₀O₁₁Na (MNa)⁺ 821.3558, found 821.3568.

Synthesis of octapeptide **2**²

Scheme S3



NH₂-L-Ala-*D*-Ala-OMe **23**: To a solution of dipeptide **20** (0.3 g, 1.1 mmol, 1.0 equiv) in DCM (7.0 mL) was added trifluoroacetic acid (1.3 g, 10.9 mmol, 10.0 equiv) and the reaction mixture was allowed to stir for 3h at RT. The solvent was removed in vacuo. The resultant salt was dissolved in water and lyophilized to afford 0.3 g (99%) of dipeptide **23** as a pale yellow solid. TLC $R_f = 0.10$ (7% MeOH/ DCM).

¹H NMR (500 MHz, DMSO-*d*₆, 25 °C) δ 8.90 (d, $J = 6.5$ Hz, 1H; NH_{Ala}), 8.22 (s, 3H; NH_3^+), 4.32 (app. quin, 1H; $CH_{(Ala)}$), 3.92-3.82 (m, 1H; $CH_{(Ala)}$), 3.63 (s, 3H; OCH_3), 1.35 (d, $J = 7$ Hz, 3H; $CH_{3(Ala)}$), 1.30 (d, $J = 7$ Hz, 3H; $CH_{3(Ala)}$); **¹³C NMR** (125 MHz, DMSO-*d*₆, 25 °C) δ 172.7, 169.6, 52.1, 52.0, 48.2, 47.9, 17.3, 17.03, 17.01; **IR** (KBr pellet): ν 3068 (b), 2622 (b), 1736 (b),

1558 (s), 1458 (s), 1140 (b), 838 (s), 722 (s) cm^{-1} . **HRMS:** (ESI⁺) calcd for $\text{C}_7\text{H}_{15}\text{N}_2\text{O}_3$ (MH)⁺ 175.1083; found 175.1091.

Boc-L-Ala-AP-OH 11: To a solution of dipeptide **7** (0.4 g, 1.3 mmol, 1.0 equiv) in THF (7.0 mL) at RT were added LiOH (0.1 g, 3.3 mmol, 2.5 equiv) and water (5.0 mL). The reaction mixture was allowed to stir for 4 h. Subsequently the reaction mixture was diluted with water (10 mL) and washed with ethyl acetate (1 × 15 mL). The aqueous layer was acidified with dil HCl to pH 1 and was extracted with ethyl acetate (4 × 15 mL). The combined organic layers were dried over anhydrous sodium sulphate and concentrated in vacuo to afford 0.37 g of Boc-L-Ala-AP-OH dipeptide **11** (92%) as a white solid. This white solid was used for the next reaction without further purification. TLC R_f = 0.15 (100% ethyl acetate).

IR (KBr pellet): ν 3437 (b), 2926 (s), 2361 (s), 1716 (b), 1628 (s), 1539 (s), 1460 (s), 1379 (s) cm^{-1} ; **HRMS:**(ESI⁺) calcd for $\text{C}_{14}\text{H}_{20}\text{N}_3\text{O}_5$ (MH)⁺310.1403; found 310.1411.

Boc-L-Ala-AP-L-Ala- D-Ala-OMe 12: To a solution of L-Ala- D-Ala-OMe dipeptide **23** (0.18 g, 0.62 mmol, 1.0 equiv) and Boc-L-Ala-AP-OH dipeptide **11** (0.19 g, 0.62 mmol, 1.0 equiv) in dry DCM (7 mL) was added HCTU (0.31 g, 7.40 mmol, 1.20 equiv). DIEA (0.38 mL, 2.20 mmol, 3.60 equiv) was slowly added to the reaction mixture and the solution was allowed to stir for 12 h at RT. The solvent was evaporated in vacuo, following which the residue was diluted with ethyl acetate (15 mL). The solution was sequentially washed with water (2 × 15 mL), 5% HCl (2 × 15 mL), saturated aqueous NaHCO_3 (2 × 15 mL) and water (15 mL). The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated in vacuo. Purification by column chromatography (silica gel; 30% - 50% ethyl acetate in hexane, v/v) afforded 0.24 g (84%) of tetrapeptide **12** as a white solid. TLC R_f = 0.25 (50% ethyl acetate/ hexane)

¹H NMR (500 MHz, DMSO- d_6) δ 10.65 (s, 1H; NH_{Ar}), 8.69 (s, 1H; NH_{Ala}), 8.37 (d, J = 8.5 Hz, 1H; NH_{Ala}), 8.25 (d, J = 8.5 Hz, 1H; H_{Ar}), 7.98 (t, J = 8.0 Hz, 1H; H_{Ar}), 7.75 (d, J = 7.5 Hz, 1H; H_{Ar}), 7.17 (d, J = 6.5 Hz, 1H; NHBoc), 4.65 – 4.59 (m, 1H; $\text{CH}_{(\text{Ala})}$), 4.32 – 4.24 (m, 2H; $\text{CH}_{(\text{Ala})}$), 3.62 (s, 3H; OCH_3), 1.38 – 1.23 (m, 18H; $(\text{CH}_3)_3\text{C}$, $\text{CH}_{3(\text{Ala})}$); **¹³C NMR** (125 MHz,

DMSO-*d*₆) δ 172.9, 171.7, 162.4, 155.3, 150.8, 147.8, 140.0, 117.2, 116.5, 78.2, 67.4, 52.0, 50.4, 47.8, 28.2, 21.5, 19.6, 17.7, 16.9; **IR** (KBr pellet): ν 3391 (b), 2925 (s), 2857 (s), 2360 (b), 1677 (b), 1531 (b), 1450 (s), 1059 (b). **HRMS**: (ESI⁺) calcd for C₂₁H₃₂N₅O₇ (MH)⁺ 466.2302; found 466.2321.

H₂N-L-Ala-AP-L-Ala- D-Ala-OMe 13: To a solution of tetrapeptide **12** (0.10 g, 0.21 mmol, 1.0 equiv) in DCM (7 mL) was slowly added trifluoro acetic acid (0.20 mL, 2.10 mmol, 10.0 equiv) over a period of 5 minutes using a syringe. The reaction mixture was allowed to stir at room temperature for 3 h, following which the solvent was removed in vacuo. The product was dissolved in water (5 mL) and lyophilized to afford 0.10 g (99%) of tetrapeptide **13** as a pale yellow solid. This yellow solid was used for the next step without further purification. TLC R_f = 0.10 (15% MeOH/ DCM)

¹H NMR (500 MHz, DMSO-*d*₆, 25 °C) δ 11.22 (s, 1H; NH_{Ar}), 8.73 (d, *J* = 7 Hz, 1H; NH_{Ala}), 8.37 (d, *J* = 8.0 Hz, 1H; H_{Ar}), 8.28 (d, *J* = 4.0 Hz, 3H; NH₃⁺), 8.06 (t, *J* = 8.5 Hz, 1H; H_{Ar}), 7.82 (dd, *J* = 7.5, 0.5 Hz, H_{Ar}), 4.63 (app quint, 1H; CH_(Ala)), 4.28 (app quint, 2H; CH_(Ala)), 3.62 (s, 3H; OCH₃), 1.48 (d, *J* = 7 Hz, 3H; CH_{3(Ala)}), 1.34 (d, *J* = 7 Hz, 3H; CH_{3(Ala)}), 1.30 (d, *J* = 7.5 Hz, 3H; CH_{3(Ala)}); **¹³C NMR** (125 MHz, DMSO-*d*₆, 25 °C) δ 172.9, 171.7, 169.5, 162.2, 158.3, 158.0, 150.1, 148.0, 140.4, 118.0, 116.7, 52.0, 49.0, 47.8, 47.7, 19.6, 17.1, 16.9; **IR** (KBr pellet): ν 3439(b), 2926(s), 1676(s), 1455(s), 1314 (s), 1202(s), 1026(s). **HRMS**: (ESI⁺) calcd for C₁₆H₂₄N₅O₅ (M⁺) 366.1777; found 366.1761.

Boc-L-Ala-AP-L-Ala- D-Ala-OH 14: A solution of tetrapeptide **12** (0.24 g, 0.52 mmol, 1.00 equiv) in methanol-water (2:1, 12 mL) was treated with LiOH (0.03 g, 1.30 mmol, 2.5 equiv) at RT. The solution was allowed to stir for 6 h, following which methanol was evaporated in vacuo. The mixture was diluted with water (10 mL) and subsequently washed with ethyl acetate (2 × 15 mL). The aqueous layer was acidified with 5% aq. HCl and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were dried over anhydrous sodium sulphate, filtered and

concentrated in vacuo to afford 0.17 g of tetrapeptide **14** (71%) as a white solid. This white solid was used for the next step without further purification. TLC $R_f = 0.10$ (100 ethyl acetate).

IR (KBr pellet): ν 3429(b), 2926(s), 1662(b), 1456(s), 1338(b), 1167(s), 1026(b). **HRMS**: (ESI⁺) calcd for C₂₀H₃₀N₅O₇ (MH)⁺ 452.2145; found 452.2127.

Boc-L-Ala-AP-L-Ala- D-Ala- L-Ala-AP-L-Ala- D-Ala-OMe 2: To a solution of Boc deprotected tetrapeptide **13** (0.06 g, 0.12 mmol, 1.0 equiv) and ester deprotected tetrapeptide **14** (0.06 g, 0.12 mmol, 1.0 equiv) in CH₂Cl₂ (7 mL) was added HCTU (0.06 g, 0.15 mmol, 1.2 equiv). DIEA (0.10 mL, 4.40 mmol, 3.0 equiv) was slowly added to the reaction mixture and the solution was allowed to stir for 12 h at room temperature. The solvent was evaporated and the residue was diluted with ethyl acetate (15 mL). The solution was washed with water (4 × 15 mL). The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated in vacuo. Purification by column chromatography (alumina; 50% – 80% ethyl acetate in hexane, v/v) afforded 0.065 g (67%) of octapeptide **2** as a pale yellow solid. TLC $R_f = 0.20$ (70% ethyl acetate/ hexane); $[\alpha]_D^{33} +7.84$ (c 1.0, CHCl₃).

¹H NMR (500 MHz, DMSO-*d*₆, 25 °C) δ 10.84 (s, 1H; NH_{Ar}), 10.68 (s, 1H; NH_{Ar}), 8.78 (t, $J = 7.0$ Hz, 1H; NH), 8.58 (d, $J = 7.5$ Hz, 1H; NH), 8.41 (d, $J = 8.0$ Hz, 2H; NH), 8.29 - 8.21 (3H; NH, H_{Ar}), 8.0 - 7.91 (2H; H_{Ar}), 7.75-7.69 (2H; H_{Ar}), 7.2 - 7.18 (m, 1H; NHBoc), 4.64 - 4.51 (m, 3H; CH_(Ala)), 4.39-4.31 (m, 1H; CH_(Ala)), 4.30-4.21 (2H; CH_(Ala)), 3.61 (s, 3H; OCH₃), 1.37 (s, 9H; (CH₃)₃C), 1.35- 1.21 (18H; 6 CH_{3(Ala)}); **¹³C NMR** (125 MHz, DMSO-*d*₆, 25 °C) Overlapping peaks δ 172.5, 172.3, 172.0, 171.8, 170.3, 164.8, 162.7, 151.9, 150.6, 147.8, 145.8, 139.8, 139.5, 120.4, 117.4, 117.2, 116.5, 78.1, 59.7, 52.3, 49.9, 48.9, 48.6, 48.3, 48.1, 28.9, 28.1, 20.7, 18.9, 18.3, 17.9, 17.7; **IR** (KBr pellet): ν 3389 (b), 2926(s), 1672 (s), 1532 (s), 1450 (s), 1168 (s) 1027 (b) cm⁻¹; **HRMS**: (ESI⁺) Calculated for C₃₆H₅₀N₁₀O₁₁Na (M+ Na)⁺ 821.3558, found 821.3579.

Vesicle based fluorescence experiments.

HPTS assay in HEPES-NaCl buffer².

Preparation of vesicles

Cholesterol (1.6 mg, 4.1 μmol , 1 equiv) was added to a solution of EYPC lipids (28.4 mg, 36.9 μmol , 9 equiv) in chloroform (0.284 mL). Chloroform was removed under a stream of nitrogen and further in vacuo for 5 h at 0 °C to give a lipid film. The lipid film was hydrated with 1 mL of a buffer solution containing HPTS dye (0.1 mM HPTS, 10 mM NaCl, 100 mM HEPES) at pH 7.2. The resulting suspension was allowed to stir at room temperature for 1 h. and then subjected to five freeze-thaw cycles. The vesicle solution was placed in an ice bath and subsequently sonicated in a bath sonicator at 0-4 °C for a total time of 2 minutes (30 s on & 15 s off in degas mode). The vesicles were allowed to anneal for one hour in the refrigerator, following which they were extruded 20 times through 100 nm polycarbonate membranes using a mini-extruder from Avanti Polar Lipids. The extra-vesicular dye was removed by size exclusion chromatography using Sephadex G-50 (eluent: HEPES buffer at pH 7.2 (10 mM NaCl, 100 mM HEPES)). The milky white solution containing vesicles were collected and used for further study.

Assay Procedure

Vesicle solution (100 μL), HEPES, NaCl buffer (2.9 mL) and an appropriate amount of peptide in methanol (0.5% DMSO)³ were added to a cuvette equipped with a magnetic stir bar. The solution in the cuvette was stirred for 2 minutes before the fluorescence experiment was started. After 50 s, a solution of NaOH (20 μL , 0.5 N) was added to the vesicles. 5% Triton X (50 μL) solution was added at 250 s to achieve final equilibration of the dye. Fluorescence measurements were done at an emission wavelength of 510 nm and an excitation wavelength of 460 nm.




Figure S1. Raw fluorescence vs. time plots for HPTS assay with HEPES-NaCl buffer

Rate constant calculations

For each experiment, the curve obtained from $t = 50$ s (after addition of NaOH) to $t = 250$ s (before addition of Triton X) was fitted to Equation 1, where $(1/t_1) = k_{\text{peptide}}$. The curves were fitted using OriginPro 8.5 software.

$$y = y_0 + A_1 e^{-x/t_1} \quad (1)$$




Figure S2. Fitting of fluorescence versus time plot for HPTS assay with MeOH. Inset table shows fitting results.




Figure S3. Fitting of fluorescence versus time plot for HPTS assay with 20 μM of peptide 1. Inset table shows fitting results.




Figure S4. Fitting of fluorescence versus time plot for HPTS assay with 41 μM of peptide 1.
Inset table shows fitting results.




Figure S5. Fitting of fluorescence versus time plot for HPTS assay with 20 μM of peptide 2.
Inset table shows fitting results.




Figure S6. Fitting of fluorescence versus time plot for HPTS assay with 41 μM of peptide 2. Inset table shows fitting results.

Lucigenin assay with sodium halides^{4, 5}

Preparation of vesicles

Cholesterol (1.6 mg, 4.1 μmol , 1 equiv) was added to a solution of EYPC lipids (28.4 mg, 36.9 μmol , 9 equiv) in chloroform. Chloroform was removed under a stream of nitrogen and further in vacuo at 0 $^{\circ}\text{C}$ for 2 h to give a lipid film. The lipid film was hydrated with 1 mL of a solution containing Lucigenin dye (1.0 mM Lucigenin, 225 mM NaNO_3). The resulting suspension was allowed to stir at room temperature for 5 minutes and then subjected to five freeze-thaw cycles. The vesicle solution was placed in an ice bath and subsequently sonicated in a bath sonicator at 0-4 $^{\circ}\text{C}$ for a total time of 2 minutes (30 s on & 15 s off in degas mode), following which they were extruded 20 times through 400 nm polycarbonate membranes using a mini-extruder from Avanti Polar Lipids. The extra-vesicular dye was removed by size exclusion chromatography (SEC) using Sephadex G-50 (eluent: 225 mM NaNO_3). (Note: Carrying out the SEC twice ensured removal of majority of the extra-vesicular dye). The milky white solution containing vesicles were collected and used for further study.

Assay procedure

Vesicle solution (100 μL) and NaNO_3 (2.9 mL) was added to a cuvette equipped with a magnetic stir bar. The solution in the cuvette was stirred for 2 minutes before the fluorescence experiment was started. After 50 s, a solution of 2.0 N NaX (35 μL), where X is Cl^- , Br^- or I^- was added to the vesicles. At 100 s, an appropriate concentration of peptide in 0.5 % DMSO-MeOH was added.³ 5 % Triton X (50 μL) solution was added at 350 s to achieve final equilibration of the dye. Fluorescence measurements were done at an emission wavelength of 505 nm and an excitation wavelength of 455 nm.




Figure S7. Normalized fluorescence vs. time plots for Lucigenin assay with peptide **1** and **2** in the presence of I^- ions.

Lucigenin assay with metal chlorides

Peptide added after addition of salt

The vesicles were prepared as described above. Vesicle solution (100 μL) and the appropriate metal nitrate solution (2.9 mL) were added to a cuvette equipped with a magnetic stir bar. The solution in the cuvette was stirred for 2 minutes before the fluorescence experiment was started. After 50s, a solution of the appropriate metal chloride (2.0 N, 35 μL), where M is Na^+ , K^+ , Co^{2+} or Ni^{2+} was added to the vesicles. At 100s, an appropriate concentration of peptide in 0.5% DMSO-methanol was added.³ 5% Triton X (50 μL) solution was added at 350 s to achieve the final equilibration of the dye. Fluorescence measurements were done at an emission wavelength of 505 nm and an excitation wavelength of 455 nm.




Figure S8. Raw fluorescence vs. time plots for lucigenin assay with peptide 1 (20 μM) in the presence of different metal chlorides.




Figure S9. Normalized Fluorescence vs. time plots for lucigenin assay with peptide 2 (20 μM) in the presence of different metal chlorides.

Rate constant calculations:




Figure S10. Fitting of fluorescence versus time plot for Lucigenin entrapped vesicles with MeOH using Origin Pro 8.5 Inset table shows fitting results.




Figure S11. Fitting of fluorescence versus time plot for Lucigenin assay with 20 μ M of peptide **1** and NaCl. Inset table shows fitting results.




Figure S12. Fitting of fluorescence versus time plot for Lucigenin assay with 20 μ M of peptide **1** and KCl. Inset table shows fitting results.




Figure S13. Fitting of fluorescence versus time plot for Lucigenin assay with 20 μM of peptide **1** and CoCl_2 . Inset table shows fitting results.




Figure S14. Fitting of fluorescence versus time plot for Lucigenin assay with 20 μM of peptide **1** and NiCl_2 . Inset table shows fitting results




Figure S15. Fitting of fluorescence versus time plot for Lucigenin assay with 20 μ M of peptide 2 and NaCl. Inset table shows fitting results




Figure S16. Fitting of fluorescence versus time plot for Lucigenin assay with 20 μ M of peptide 2 and KCl. Inset table shows fitting results




Figure S17. Fitting of fluorescence versus time plot for Lucigenin assay with 20 μM of peptide 2 and CoCl_2 . Inset table shows fitting results




Figure S18. Fitting of fluorescence versus time plot for Lucigenin assay with 20 μM of peptide 2 and NiCl_2 . Inset table shows fitting results

Peptide premixed with vesicles

The vesicles were prepared as described above. Vesicle solution (100 μL) and the appropriate metal nitrate solution (2.9 mL) and an appropriate amount of peptide in methanol (0.5% DMSO)³ were added to a cuvette equipped with a magnetic stir bar. The solution in the cuvette was stirred for 2 minutes before the fluorescence experiment was started. After 100s, a solution of the appropriate metal chloride (2.0 N, 35 μL), where M is Na^+ , K^+ , Co^{2+} or Ni^{2+} was added to the vesicles. 5% Triton X (50 μL) solution was added at 400 s to achieve the final equilibration of the dye. Fluorescence measurements were done at an emission wavelength of 505 nm and an excitation wavelength of 455 nm.




Figure S19. Normalized Fluorescence vs. time plots for lucigenin assay with peptide **1** (20 μM) premixed in the presence of different metal chlorides.




Figure S20. Normalized Fluorescence vs. time plots for lucigenin assay with peptide 2 (20 μM) premixed in the presence of different metal chlorides.




Figure S21. Fitting of fluorescence versus time plot for Lucigenin entrapped vesicles with MeOH using Origin Pro 8.5 Inset table shows fitting results.




Figure S22. Fitting of fluorescence versus time plot for Lucigenin assay with 20 μM of peptide **1** (premixed) and NaCl. Inset table shows fitting results




Figure S23. Fitting of fluorescence versus time plot for Lucigenin assay with 20 μM of peptide **1** (premixed) and KCl. Inset table shows fitting results




Figure S24. Fitting of fluorescence versus time plot for Lucigenin assay with 20 μM of peptide **1** (premixed) and CoCl_2 . Inset table shows fitting results




Figure S25. Fitting of fluorescence versus time plot for Lucigenin assay with 20 μM of peptide **1** (premixed) and NiCl_2 . Inset table shows fitting results.




Figure S26. Fitting of fluorescence versus time plot for Lucigenin assay with 20 μM of peptide 2 (premixed) and NaCl. Inset table shows fitting results.




Figure S27. Fitting of fluorescence versus time plot for Lucigenin assay with 20 μM of peptide 2 (premixed) and KCl. Inset table shows fitting results.




Figure S28. Fitting of fluorescence versus time plot for Lucigenin assay with 20 μM of peptide 2 (premixed) and CoCl_2 . Inset table shows fitting results.




Figure S29. Fitting of fluorescence versus time plot for Lucigenin assay with 20 μM of peptide 2 (premixed) and NiCl_2 . Inset table shows fitting results.

Dynamic light scattering studies

For the blank readings, 20 μL of MeOH was added to vesicle solutions (100 μL) diluted with HEPES buffer (2.9 mL). For measurement with peptides, an appropriate concentration of peptide in MeOH was added to the vesicle solution.




Figure S30. Dynamic light scattering study with octapeptide **1** (41 μM) and vesicles




Figure S31. Dynamic light scattering study with octapeptide 2 (41 μM) and vesicles

TEM studies

Sample preparation

A solution of peptide (3.2 mg/mL) in 1% DMSO-MeOH was kept for 48 h at 0 °C. A small amount of this solution (5 μL) was placed on a carbon-coated Copper grid using a micropipette. The loaded support was dried in vacuo for 6 h before TEM images were collected.

Planar Lipid Bilayer Experiment

The ion transport through the peptide channels was also investigated with Planar lipid bilayer (PLB) recording. Synthetic lipid 1,2-diphytanoyl-sn-glycero-3-phosphocholine (Avanti Polar Lipids, Alabaster, AL) was dissolved in n-decane at a concentration of 20 mg/ml and used to make the lipid bilayer. Briefly, the lipid was painted on to the aperture (pore diameter of 150 μm) of a polystyrene bilayer cuvette (Warner Instruments, USA). Both chambers of the cuvette

contained symmetrical solution (1 M KCl). The cis chamber was held at virtual ground and the trans chamber connected to a recording amplifier via a PC501A head-stage (Warner instrument). Ag-AgCl electrodes were used. Currents were low pass filtered at 1 kHz and digitized at 5 kHz using the Digidata 1440A (Axon Instruments). Once a stable bilayer was obtained, the synthetic peptide was added to the cis chamber and mixed with a magnetic stirrer. Membrane currents were frequently checked to monitor channel incorporation. After stable insertion of the peptides in bilayer, membrane current was recorded at different positive and negative voltages. For measuring reversal potential, the solution of the cis chamber was replaced with 0.5 M KCl while the trans chamber had 1 M KCl. Theoretical reversal potential was estimated using the Nernst Equation and compared with the experimentally derived value.

Absorbance Measurements of Peptides with CoCl_2 and NiCl_2 :

For complexation studies, peptide and chloride salt were mixed at a ratio of 1: 5.4×10^3 which is exactly the same as the peptide to salt ratio used for vesicle bound fluorescence assay.




Figure S32. Absorbance spectra to check binding of peptide 1 with a) CoCl_2 and b) NiCl_2 .




Figure S33. Absorbance spectra to check binding of peptide **2** with a) CoCl₂ and b) NiCl₂

References and notes:

- 1) M. Jonathan Fray; A. T. Gillmore; M. S. Slossop; D. J. McManus; I. B. Moses and C. F.B. Praquin, *Org. Proc. Res. Develop.* 2010, **14**, 263.
- 2) B. P. Benke and N. Madhavan, *Chem. Commun.* 2013, **49**, 7340.
- 3) Peptide solution was made 3 days before experiment.
- 4) B. A. McNally, A. V. Koulov, B. D. Smith, J.-B. Joos and A. P. Davis, *Chem. Commun.*, 2005, 1087.
- 5) N. Madhavan and M. S. Gin, *ChemBioChem.* 2007, **8**, 1834.

Spectra of compounds

